Harvard Bioscience, Inc. (NASDAQ: HBIO) Stock Competitors & Peer Comparison
See HBIO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HBIO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HBIO | $8.09 | +0.75% | 36.5M | -22.47 | -$0.36 | N/A |
| ISRG | $377.94 | +2.38% | 133.5B | 39.29 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| BDX | $182.91 | +2.85% | 50.4B | 14.07 | $13.00 | +2.25% |
| RMD | $222.99 | +2.16% | 32.3B | 20.70 | $10.77 | +1.13% |
| MDLN | $32.59 | +0.18% | 27.6B | 23.88 | $1.36 | N/A |
| WST | $355.20 | +2.59% | 25B | 41.78 | $8.50 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $89.82 | +2.71% | 15.6B | 12.65 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
HBIO vs ISRG Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ISRG has a market cap of 133.5B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ISRG trades at $377.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ISRG's P/E ratio is 39.29. In terms of profitability, HBIO's ROE is -0.92%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, HBIO is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
HBIO vs BDXA Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BDXA's P/E ratio is 45.70. In terms of profitability, HBIO's ROE is -0.92%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
HBIO vs BDX Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BDX has a market cap of 50.4B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BDX trades at $182.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BDX's P/E ratio is 14.07. In terms of profitability, HBIO's ROE is -0.92%, compared to BDX's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
HBIO vs RMD Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, RMD has a market cap of 32.3B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while RMD trades at $222.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas RMD's P/E ratio is 20.70. In terms of profitability, HBIO's ROE is -0.92%, compared to RMD's ROE of +0.24%. Regarding short-term risk, HBIO is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
HBIO vs MDLN Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, MDLN has a market cap of 27.6B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while MDLN trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas MDLN's P/E ratio is 23.88. In terms of profitability, HBIO's ROE is -0.92%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, HBIO is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
HBIO vs WST Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, WST has a market cap of 25B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while WST trades at $355.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas WST's P/E ratio is 41.78. In terms of profitability, HBIO's ROE is -0.92%, compared to WST's ROE of +0.19%. Regarding short-term risk, HBIO is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
HBIO vs HOLX Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas HOLX's P/E ratio is 31.54. In terms of profitability, HBIO's ROE is -0.92%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, HBIO is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
HBIO vs SOLV Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while SOLV trades at $89.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas SOLV's P/E ratio is 12.65. In terms of profitability, HBIO's ROE is -0.92%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, HBIO is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
HBIO vs BDXB Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BDXB's P/E ratio is 7.60. In terms of profitability, HBIO's ROE is -0.92%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
HBIO vs BAX Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BAX trades at $23.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BAX's P/E ratio is 11.47. In terms of profitability, HBIO's ROE is -0.92%, compared to BAX's ROE of -0.17%. Regarding short-term risk, HBIO is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
HBIO vs COO Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, COO has a market cap of 10.6B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while COO trades at $54.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas COO's P/E ratio is 11.88. In terms of profitability, HBIO's ROE is -0.92%, compared to COO's ROE of +0.07%. Regarding short-term risk, HBIO is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
HBIO vs AVTR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, AVTR has a market cap of 10.2B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while AVTR trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas AVTR's P/E ratio is 17.82. In terms of profitability, HBIO's ROE is -0.92%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, HBIO is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
HBIO vs RGEN Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, RGEN has a market cap of 9.5B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while RGEN trades at $168.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas RGEN's P/E ratio is 93.33. In terms of profitability, HBIO's ROE is -0.92%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, HBIO is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
HBIO vs ATR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ATR trades at $124.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ATR's P/E ratio is 21.84. In terms of profitability, HBIO's ROE is -0.92%, compared to ATR's ROE of +0.14%. Regarding short-term risk, HBIO is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
HBIO vs BLCO Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BLCO has a market cap of 6.3B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BLCO trades at $17.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BLCO's P/E ratio is 27.06. In terms of profitability, HBIO's ROE is -0.92%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, HBIO is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
HBIO vs STVN Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while STVN trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas STVN's P/E ratio is 32.22. In terms of profitability, HBIO's ROE is -0.92%, compared to STVN's ROE of +0.09%. Regarding short-term risk, HBIO is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
HBIO vs TFX Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while TFX trades at $130.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas TFX's P/E ratio is 14.87. In terms of profitability, HBIO's ROE is -0.92%, compared to TFX's ROE of -0.32%. Regarding short-term risk, HBIO is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
HBIO vs MMSI Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while MMSI trades at $87.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas MMSI's P/E ratio is 22.26. In terms of profitability, HBIO's ROE is -0.92%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, HBIO is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
HBIO vs NVST Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, NVST has a market cap of 4.2B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while NVST trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas NVST's P/E ratio is 17.54. In terms of profitability, HBIO's ROE is -0.92%, compared to NVST's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
HBIO vs ICUI Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ICUI trades at $157.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ICUI's P/E ratio is 19.68. In terms of profitability, HBIO's ROE is -0.92%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, HBIO is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
HBIO vs PLSE Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while PLSE trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas PLSE's P/E ratio is -45.94. In terms of profitability, HBIO's ROE is -0.92%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, HBIO is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
HBIO vs ATRC Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ATRC trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ATRC's P/E ratio is 1732.61. In terms of profitability, HBIO's ROE is -0.92%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, HBIO is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
HBIO vs XRAY Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while XRAY trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas XRAY's P/E ratio is 7.26. In terms of profitability, HBIO's ROE is -0.92%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, HBIO is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
HBIO vs LMAT Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while LMAT trades at $80.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas LMAT's P/E ratio is 29.69. In terms of profitability, HBIO's ROE is -0.92%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, HBIO is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
HBIO vs BLFS Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BLFS trades at $35.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BLFS's P/E ratio is -167.64. In terms of profitability, HBIO's ROE is -0.92%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, HBIO is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
HBIO vs AZTA Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while AZTA trades at $32.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas AZTA's P/E ratio is 76.29. In terms of profitability, HBIO's ROE is -0.92%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, HBIO is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
HBIO vs KMTS Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, KMTS has a market cap of 1.4B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while KMTS trades at $24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas KMTS's P/E ratio is -10.19. In terms of profitability, HBIO's ROE is -0.92%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, HBIO is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
HBIO vs STAA Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while STAA trades at $23.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas STAA's P/E ratio is 40.47. In terms of profitability, HBIO's ROE is -0.92%, compared to STAA's ROE of +0.01%. Regarding short-term risk, HBIO is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
HBIO vs ATRI Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ATRI's P/E ratio is 64.50. In terms of profitability, HBIO's ROE is -0.92%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, HBIO is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
HBIO vs ANGO Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ANGO has a market cap of 641.1M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ANGO trades at $15.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ANGO's P/E ratio is -39.77. In terms of profitability, HBIO's ROE is -0.92%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, HBIO is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
HBIO vs SMTI Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, SMTI has a market cap of 321.6M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while SMTI trades at $34.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas SMTI's P/E ratio is -583.00. In terms of profitability, HBIO's ROE is -0.92%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, HBIO is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
HBIO vs EMBC Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, EMBC has a market cap of 310.9M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while EMBC trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas EMBC's P/E ratio is 2.02. In terms of profitability, HBIO's ROE is -0.92%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, HBIO is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
HBIO vs NNNN Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, NNNN has a market cap of 268.2M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while NNNN trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas NNNN's P/E ratio is 88.29. In terms of profitability, HBIO's ROE is -0.92%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, HBIO is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
HBIO vs OSUR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, OSUR has a market cap of 232M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while OSUR trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas OSUR's P/E ratio is -4.88. In terms of profitability, HBIO's ROE is -0.92%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, HBIO is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
HBIO vs UTMD Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, UTMD has a market cap of 225M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while UTMD trades at $70.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas UTMD's P/E ratio is 20.91. In terms of profitability, HBIO's ROE is -0.92%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, HBIO is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
HBIO vs PDEX Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, PDEX has a market cap of 212.5M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while PDEX trades at $66.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas PDEX's P/E ratio is 16.12. In terms of profitability, HBIO's ROE is -0.92%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, HBIO is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
HBIO vs KRMD Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, KRMD has a market cap of 144.2M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while KRMD trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas KRMD's P/E ratio is -78.50. In terms of profitability, HBIO's ROE is -0.92%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, HBIO is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
HBIO vs STXS Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, STXS has a market cap of 130.7M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while STXS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas STXS's P/E ratio is -7.85. In terms of profitability, HBIO's ROE is -0.92%, compared to STXS's ROE of -1.33%. Regarding short-term risk, HBIO is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
HBIO vs DXR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, DXR has a market cap of 65.8M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while DXR trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas DXR's P/E ratio is 9.17. In terms of profitability, HBIO's ROE is -0.92%, compared to DXR's ROE of +0.13%. Regarding short-term risk, HBIO is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
HBIO vs AKYA Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas AKYA's P/E ratio is -1.34. In terms of profitability, HBIO's ROE is -0.92%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, HBIO is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
HBIO vs STSS Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas STSS's P/E ratio is -0.02. In terms of profitability, HBIO's ROE is -0.92%, compared to STSS's ROE of -1.54%. Regarding short-term risk, HBIO is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
HBIO vs OMIC Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas OMIC's P/E ratio is -0.58. In terms of profitability, HBIO's ROE is -0.92%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, HBIO is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
HBIO vs IGAP Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas IGAP's P/E ratio is -10.52. In terms of profitability, HBIO's ROE is -0.92%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, HBIO is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
HBIO vs NEPH Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, NEPH has a market cap of 48.1M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while NEPH trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas NEPH's P/E ratio is 73.83. In terms of profitability, HBIO's ROE is -0.92%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, HBIO is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
HBIO vs POCI Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, POCI has a market cap of 47.5M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while POCI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas POCI's P/E ratio is -6.89. In terms of profitability, HBIO's ROE is -0.92%, compared to POCI's ROE of -0.37%. Regarding short-term risk, HBIO is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
HBIO vs MLSS Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, MLSS has a market cap of 37.5M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while MLSS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas MLSS's P/E ratio is -8.48. In terms of profitability, HBIO's ROE is -0.92%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, HBIO is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
HBIO vs SDC Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas SDC's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.92%, compared to SDC's ROE of -1.96%. Regarding short-term risk, HBIO is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
HBIO vs IVC Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas IVC's P/E ratio is -0.79. In terms of profitability, HBIO's ROE is -0.92%, compared to IVC's ROE of -0.46%. Regarding short-term risk, HBIO is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
HBIO vs RVP Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas RVP's P/E ratio is -5.72. In terms of profitability, HBIO's ROE is -0.92%, compared to RVP's ROE of -0.05%. Regarding short-term risk, HBIO is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
HBIO vs BNGO Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, BNGO has a market cap of 15.3M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while BNGO trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas BNGO's P/E ratio is -0.30. In terms of profitability, HBIO's ROE is -0.92%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, HBIO is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
HBIO vs ZJYL Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ZJYL has a market cap of 15M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ZJYL trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ZJYL's P/E ratio is 13.13. In terms of profitability, HBIO's ROE is -0.92%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
HBIO vs RGNT Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, RGNT has a market cap of 13.3M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while RGNT trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas RGNT's P/E ratio is -0.08. In terms of profitability, HBIO's ROE is -0.92%, compared to RGNT's ROE of N/A. Regarding short-term risk, HBIO is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
HBIO vs CUPR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, CUPR has a market cap of 8.5M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while CUPR trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas CUPR's P/E ratio is -2.29. In terms of profitability, HBIO's ROE is -0.92%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, HBIO is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
HBIO vs FEMY Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, FEMY has a market cap of 7.9M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while FEMY trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas FEMY's P/E ratio is -0.58. In terms of profitability, HBIO's ROE is -0.92%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, HBIO is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
HBIO vs LUCY Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while LUCY trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas LUCY's P/E ratio is -0.49. In terms of profitability, HBIO's ROE is -0.92%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, HBIO is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
HBIO vs NSTG Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas NSTG's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.92%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, HBIO is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
HBIO vs POAI Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas POAI's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.92%, compared to POAI's ROE of -21.19%. Regarding short-term risk, HBIO is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
HBIO vs MHUA Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas MHUA's P/E ratio is 0.25. In terms of profitability, HBIO's ROE is -0.92%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, HBIO is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
HBIO vs NXGL Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while NXGL trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas NXGL's P/E ratio is -0.40. In terms of profitability, HBIO's ROE is -0.92%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, HBIO is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
HBIO vs GMVD Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas GMVD's P/E ratio is -0.01. In terms of profitability, HBIO's ROE is -0.92%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, HBIO is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
HBIO vs GMVDW Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas GMVDW's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.92%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, HBIO is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
HBIO vs AVGR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas AVGR's P/E ratio is -0.05. In terms of profitability, HBIO's ROE is -0.92%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, HBIO is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
HBIO vs NXGLW Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, NXGLW has a market cap of 1.1M. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, HBIO's ROE is -0.92%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, HBIO is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
HBIO vs LUCYW Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas LUCYW's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.92%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, HBIO is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
HBIO vs APR Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, APR has a market cap of 0. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas APR's P/E ratio is 22.59. In terms of profitability, HBIO's ROE is -0.92%, compared to APR's ROE of +9.81%. Regarding short-term risk, HBIO is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
HBIO vs IIN Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, IIN has a market cap of 0. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas IIN's P/E ratio is 226.45. In terms of profitability, HBIO's ROE is -0.92%, compared to IIN's ROE of -0.00%. Regarding short-term risk, HBIO is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
HBIO vs ALOG Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ALOG's P/E ratio is 40.93. In terms of profitability, HBIO's ROE is -0.92%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, HBIO is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
HBIO vs IVTY Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas IVTY's P/E ratio is -3.80. In terms of profitability, HBIO's ROE is -0.92%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, HBIO is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
HBIO vs ATRS Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas ATRS's P/E ratio is 14.95. In terms of profitability, HBIO's ROE is -0.92%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, HBIO is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
HBIO vs HRC Comparison September 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 36.5M. In comparison, HRC has a market cap of 0. Regarding current trading prices, HBIO is priced at $8.09 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -22.47, whereas HRC's P/E ratio is 41.92. In terms of profitability, HBIO's ROE is -0.92%, compared to HRC's ROE of +0.14%. Regarding short-term risk, HBIO is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check HRC's competition here